Indications for: RETAVASE
Treatment of acute ST-elevation myocardial infarction (STEMI) to reduce the risk of death and heart failure.
Limitations of Use:
The risk of stroke may outweigh the benefit produced by thrombolytic
therapy in patients whose STEMI puts them at low risk for death or heart failure.
Start as soon as possible after onset of STEMI. 10 units IV over 2mins; repeat with 10 units 30mins after the first dose.
Active internal bleeding. Recent stroke. Intracranial or intraspinal surgery or serious head trauma within 3 months. Intracranial neoplasm, arteriovenous malformation, or aneurysm. Bleeding diathesis. Severe uncontrolled hypertension.
Avoid noncompressible arterial puncture, internal jugular and subclavian venous punctures, IM inj, nonessential handling of patient to minimize risk of bleeding. Withhold second dose if serious bleeding or anaphylactoid reaction occurs. Discontinue concomitant anticoagulant therapy if severe bleeding occurs. Cholesterol embolization. Pregnancy. Nursing mothers: not studied.
Tissue plasminogen activator (tPA).
Increased bleeding risk with concomitant anticoagulant therapy. Incompatible with heparin; do not administer through an IV line together. Coagulation tests may be unreliable during therapy.
Bleeding, hypersensitivity reactions, cholesterol embolism.
Renal. Half-life: 13–16 minutes.
Kit—1 (2 vials w. diluents, supplies); Half-Kit—1 (1 vial w. diluent, supplies)